Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies

Christoph Licht; Larry A. Greenbaum; Petra Muus; Sunil Babu; Camille L. Bedrosian; David J. Cohen; Yahsou Delmas; Kenneth Douglas; Richard R. Furman; Osama Gaber; Timothy H.J. Goodship; Maria Herthelius; Maryvonne Hourmant; Christophe Legendre; Giuseppe Remuzzi; Neil Sheerin; Antonella Trivelli; Chantal Loirat

doi:10.1038/ki.2014.423

Related publications

Article2013

Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome

Christophe Legendre, Christoph Licht, Petra Muus, Larry A. Greenbaum, Sunil Babu, Camille L. Bedrosian, Coralie Bingham, D.J. Cohen, Yahsou Delmas, K. Douglas, Frank Eitner, Thorsten Feldkamp, Denis Fouque, Richard R. Furman, Osama Gaber, Maria Herthelius, Maryvonne Hourmant, Diana Karpman, Yvon Lebranchu, Christophe Mariat, Jan Menne, Bruno Moulin, Jens Nürnberger, Masayo Ogawa, Giuseppe Remuzzi, Tristan Richard, Rébecca Sberro‐Soussan, Beth Severino, N. Sheerin, Antonella Trivelli, Lothar Bernd Zimmerhackl, Tim Goodship, Chantal Loirat

Letter2009

More on Eculizumab for Congenital Atypical Hemolytic–Uremic Syndrome

Jae Il Shin, Jae Seung Lee

Article2015

Sustained efficacy and safety of eculizumab in patients with atypical hemolytic uremic syndrome with long disease duration and chronic kidney disease: 3-year update

Yahsou Delmas, Chantal Loirat, Petra Muus, Christophe Legendre, Kenneth Douglas, Maryvonne Hourmant, Maria Herthelius, Antonella Trivelli, Timothy H.J. Goodship, Giuseppe Remuzzi, Camille L. Bedrosian, Christoph Licht

Article2009

Atypical Hemolytic–Uremic Syndrome

Marina Noris, Giuseppe Remuzzi

Article2016

Genetic Atypical Hemolytic-Uremic Syndrome

Marina Noris, Elena Bresin, Caterina Mele, Giuseppe Remuzzi